Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trivalent influenza vaccine (Moderna Inc)
- Development stage
- Unknown
- Lead developer
- Moderna
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Trivalent influenza vaccine (TIV) is an inactivated viral vaccine designed to provide protection against three different strains of the influenza virus: typically two subtypes of influenza A (H1N1 and H3N2) and one lineage of influenza B. This specific entry refers to the vaccine evaluated by the University of Colorado, Denver, in a Phase 4 clinical trial in India (NCT00344916). The study investigated the efficacy of spring-administered vaccination in children aged 6 months to 10 years and its potential for indirect protection of household members. The vaccine works by inducing the production of antibodies against the viral hemagglutinin and neuraminidase proteins, thereby preventing viral entry and spread within the host.
- Other names
- Inactivated Trivalent Influenza VaccineTIV
02
Targets
NeuraminidaseHA (Hemagglutinin)
Beyond the preview
Go deeper on trivalent influenza vaccine (Moderna Inc).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trivalent influenza vaccine (Moderna Inc).